MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10557-020-07087-6

Медицинская библиотека · Cardiovascular drugs and therapy · 2021

One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration.

Chandrasekhar Jaya, de Winter Vera C, Kalkman Deborah N, Sartori Samantha, Chandiramani Rishi, Aquino Melissa B, de Wilde Puk, Zeebregts Doreen, Woudstra Pier, Beijk Marcel A, Hájek Petr, Atzev Borislav, Hudec Martin, Ong Tiong Kiam, Mates Martin, Borisov Borislav, Warda Hazem M, den Heijer Peter, Wojcik Jaroslaw, Iniguez Andres, Coufal Zdeněk, Lee Michael, Tijssen Jan G, Koch Karel T, Baber Usman, Dangas George D, Colombo Antonio, de Winter Robbert J, Mehran Roxana, MASCOT and REMEDEE investigators (Appendix I)

СтатьяПеревод в очереди

Аннотация

PURPOSE: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent by ACS status and ACS subtype.

METHODS

The COMBO collaboration (n = 3614) is a patient-level pooled dataset from the MASCOT and REMEDEE registries. We evaluated outcomes by ACS status, and ACS subtype in patients with ST segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) versus unstable angina (UA). The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Secondary outcomes included stent thrombosis (ST).

RESULTS

We compared 1965 (54%) ACS and 1649 (46.0%) non-ACS patients. ACS presentations included 40% (n = 789) STEMI, 31% (n = 600) NSTEMI, and 29% (n = 576) UA patients. Risk of 1-year TLF was greater in ACS patients (4.5% vs. 3.3%, HR 1.51 95% CI 1.01-2.25, p = 0.045) without significant differences in definite/probable ST (1.1% vs 0.5%, HR 2.40, 95% CI 0.91-6.31, p = 0.08). One-year TLF was similar in STEMI, NSTEMI, and UA (4.8% vs 4.8% vs. 3.7%, p = 0.60), but definite/probable ST was higher in STEMI patients (1.9% vs 0.5% vs 0.7%, p = 0.03). Adjusted outcomes were not different in MI versus UA patients.

CONCLUSIONS

Despite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes.

Для цитирования: Chandrasekhar Jaya, de Winter Vera C, Kalkman Deborah N, Sartori Samantha, Chandiramani Rishi, Aquino Melissa B, de Wilde Puk, Zeebregts Doreen, Woudstra Pier, Beijk Marcel A, Hájek Petr, Atzev Borislav, Hudec Martin, Ong Tiong Kiam, Mates Martin, Borisov Borislav, Warda Hazem M, den Heijer Peter, Wojcik Jaroslaw, Iniguez Andres, Coufal Zdeněk, Lee Michael, Tijssen Jan G, Koch Karel T, Baber Usman, Dangas George D, Colombo Antonio, de Winter Robbert J, Mehran Roxana, MASCOT and REMEDEE investigators (Appendix I). One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration.. Cardiovascular drugs and therapy. 2021. DOI: 10.1007/s10557-020-07087-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.